Key result
Hormone therapy is linked to higher depression scores, driven primarily by sexual anhedonia.
Why the study?
The effects of hormone therapy on depression and depressive symptoms in prostate cancer patients undergoing 6 months of treatment were investigated to clarify this association.
Does hormone therapy increase depression and depressive symptoms in prostate cancer patients?
Cohort (n=102)
Does hormone therapy increase depression and depressive symptoms in prostate cancer patients?
Hormone therapy in prostate cancer patients is associated with increased depression, which appears to be dominated by sexual anhedonia resulting from decreased sexual performance.
No takes yet. Share an insight, caveat, or question.
May support monitoring for sexual anhedonia in prostate cancer patients on hormone therapy; leaves open causal inference from observational data.
Sharpley et al. (2016) conducted a cohort in Prostate cancer (n=102). Hormone therapy vs. Baseline (before hormone therapy) was evaluated on Zung Self-rating Depression Scale (SDS) scores. Hormone therapy was associated with a significant increase in depression scores, with increases restricted to 8 of the 20 SDS symptoms, most notably sexual anhedonia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: